production19 dec 2016
Mr. Bruce Pritchard, ProMetic’s Chief Operating Officer, stated: “We are already prepared to accommodate the existing plasminogen product needs of the congenitally deficient patients with our current manufacturing capacity” who added, “We are also prepared for the expected product requirements arising from additional clinical indications treated with plasminogen that will follow the initial commercial launch”.